Sertraline

Results: 435



#Item
341DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Parts 201, 312, 314, and 601 [Docket No. 97N[removed]RIN 0910-AB20 Regulations Requiring Manufacturers to Assess the Safety and

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Parts 201, 312, 314, and 601 [Docket No. 97N[removed]RIN 0910-AB20 Regulations Requiring Manufacturers to Assess the Safety and

Add to Reading List

Source URL: ctep.cancer.gov

Language: English - Date: 2008-09-22 21:29:15
342Food and Drug Administration Center for Drug Evaluation and Research SUMMARY MINUTES OF THE CDER PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE AND THE FDA PEDIATRIC ADVISORY COMMITTEE

Food and Drug Administration Center for Drug Evaluation and Research SUMMARY MINUTES OF THE CDER PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE AND THE FDA PEDIATRIC ADVISORY COMMITTEE

Add to Reading List

Source URL: www.fda.gov

Language: English - Date: 2004-10-05 15:26:15
343PEEHIP Step Therapy List PEEHIP utilizes the following Step Therapy programs to ensure that prescription use by PEEHIP members is safe and affordable. As a PEEHIP member, you should be aware of the following Step Therapy

PEEHIP Step Therapy List PEEHIP utilizes the following Step Therapy programs to ensure that prescription use by PEEHIP members is safe and affordable. As a PEEHIP member, you should be aware of the following Step Therapy

Add to Reading List

Source URL: www.rsa-al.gov

Language: English - Date: 2014-05-08 15:51:27
344FDA Approved Labeling[removed]3pm NovaDel Pharma Inc. Zolpimist (zolpidem tartrate) Oral Spray •	  CNS-depressant effects: Use can impair alertness and motor

FDA Approved Labeling[removed]3pm NovaDel Pharma Inc. Zolpimist (zolpidem tartrate) Oral Spray • CNS-depressant effects: Use can impair alertness and motor

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2009-03-31 14:11:06
345Microsoft PowerPoint - HCPs EN Jan 12_07.pps

Microsoft PowerPoint - HCPs EN Jan 12_07.pps

Add to Reading List

Source URL: www.hc-sc.gc.ca

Language: English - Date: 2013-07-09 12:42:51
346NDA[removed]S-014 & S-016 NDA[removed]S-008 & S-009 NDA[removed]S-003 & S-005 FDA Final Labeling Text dated[removed]Page 1 HIGHLIGHTS OF PRESCRIBING INFORMATION

NDA[removed]S-014 & S-016 NDA[removed]S-008 & S-009 NDA[removed]S-003 & S-005 FDA Final Labeling Text dated[removed]Page 1 HIGHLIGHTS OF PRESCRIBING INFORMATION

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-09-27 15:15:17
347Frequently Asked Questions  Premenstrual Syndrome http://www.womenshealth.gov

Frequently Asked Questions Premenstrual Syndrome http://www.womenshealth.gov

Add to Reading List

Source URL: www.womenshealth.gov

Language: English - Date: 2014-01-03 17:20:31
348Vesicare (solifenacin succinate) tablets label

Vesicare (solifenacin succinate) tablets label

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2010-07-13 11:37:34
349

PDF Document

Add to Reading List

Source URL: www.fda.gov

Language: English
35025 YEARS AFTER PROZAC  ANTIDEPRESSANTS STILL OFFER HIGH MARKET POTENTIAL Last year marked the 25th anniversary of the U.S.-launch of the iconic antidepressant, Prozac. This medical breakthrough led to a series of new med

25 YEARS AFTER PROZAC ANTIDEPRESSANTS STILL OFFER HIGH MARKET POTENTIAL Last year marked the 25th anniversary of the U.S.-launch of the iconic antidepressant, Prozac. This medical breakthrough led to a series of new med

Add to Reading List

Source URL: sciencewatch.com

Language: English - Date: 2014-07-07 12:47:46